ID: ALA454811

Max Phase: Preclinical

Molecular Formula: C11H10O5

Molecular Weight: 222.20

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc2c(c1C=O)CC(O)OC2=O

Standard InChI:  InChI=1S/C11H10O5/c1-15-9-3-2-6-7(8(9)5-12)4-10(13)16-11(6)14/h2-3,5,10,13H,4H2,1H3

Standard InChI Key:  JTWDUAARTVHRFU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 222.20

Molecular Weight (Monoisotopic): 222.0528

AlogP: 0.54

#Rotatable Bonds: 2

Polar Surface Area: 72.83

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.06

CX Basic pKa:

CX LogP: 0.78

CX LogD: 0.78

Aromatic Rings: 1

Heavy Atoms: 16

QED Weighted: 0.58

Np Likeness Score: 1.50

References

1. Ling Q, Huang Y, Zhou Y, Cai Z, Xiong B, Zhang Y, Ma L, Wang X, Li X, Li J, Shen J..  (2008)  Illudalic acid as a potential LAR inhibitor: synthesis, SAR, and preliminary studies on the mechanism of action.,  16  (15): [PMID:18579388] [10.1016/j.bmc.2008.06.014]

2. McCullough BS, Batsomboon P, Hutchinson KB, Dudley GB, Barrios AM..  (2019)  Synthesis and PTP Inhibitory Activity of Illudalic Acid and Its Methyl Ether, with Insights into Selectivity for LAR PTP over Other Tyrosine Phosphatases under Physiologically Relevant Conditions.,  82  (12): [PMID:31809044] [10.1021/acs.jnatprod.9b00663]

Source

Source(1):

• Scientific Literature